Shilpa Gupta: Stellar talk by Neeraj Agarwal on tremendous progress in mCRpC in Athens

Shilpa Gupta shared a post on X:

“Stellar talk by Neeraj Agarwal on tremendous progress in Metastatic castration-resistant prostate cancer (mCRPC)  in Athens. Lot of progress with Poly adenosine diphosphate ribose polymerase inhibitors (PARPi), radiologands, Proteolysis targeting chimeric (PROTAC), Chimeric Antigen Receptor T-cell therapy (CAR-T), Cabo, Bispecific T-cell engager (BiTE), Antibody-Drug Conjugates (ADCs) but sobering to see majority of patients not exposed to ARPIs in United States.”

Sumanta K.Pal shared a post on X:

“Very much missing this stellar crew, who are bringing down the house in Athens with a series of terrific talks. Neeraj Agarwal, Shilpa Gupta, Naomi Haas, Philippe Spiess make up just part of an exciting roster – well done organizing Petros Grivas.”

Source: Sumanta K.Pal/X and Shilpa Gupta/X

Dr. Shilpa Gupta is the Director of Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. Dr. Gupta’s extensive research focuses on novel drug development and biomarkers of response/resistance in bladder cancer, contributing to numerous published works and leadership roles in clinical trials.

Sumanta (Monty) Pal, MD, is a medical oncologist and an expert in genitourinary cancers at the City of Hope Comprehensive Cancer Center in Los Angeles. He serves as the co-director of the Kidney Cancer Program and leads the Kidney and Bladder Cancer Disease Team at City of Hope. He specialises in kidney, bladder, and prostate cancers.